Clinical Trial Update: Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667 [Phase 2]

View source ↗

Summary

A Phase 2 randomized, double-blind study of BAY58-2667 for congestive heart failure sponsored by Bayer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• BAY58-2667

Snippet

Sponsor: Bayer | Conditions: Congestive Heart Failure | Phase 2 | Status: TERMINATED